BACKGROUND: Ketamine rapidly improves depressive symptoms in patients with treatment-resistant major depressive disorder (MDD) who do not respond to multiple standard antidepressants. However, it remains unknown whether ketamine is equally effective in patients with MDD who previously also did not respond to electroconvulsive therapy (ECT). METHODS: This study compared 17 patients with treatment-resistant MDD who previously did not respond to ECT and 23 patients with treatment-resistant MDD who had not previously received ECT. All subjects received a single open-label infusion of ketamine (0.5 mg/kg). Patients were evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS) at baseline (60 min before the infusion), as well as at 40, 80, 120, and 230 min after infusion. RESULTS: Depressive symptoms were significantly improved in the ECT-resistant group at 230 minutes with a moderate effect size (p < .001, d = 0.50, 95% C.I.: 0.21-0.80). At 230 minutes, the non-ECT exposed group showed significant improvement with a large effect size (p < .001, d=1.00, 95% C.I.: 0.71-1.29). CONCLUSION: Ketamine appears to improve depressive symptoms in patients with MDD who had previously not responded to ECT. These preliminary results encourage further investigation with a larger sample size to determine effectiveness compared to other treatment-resistant patients with MDD. Published by Elsevier Inc.
BACKGROUND:Ketamine rapidly improves depressive symptoms in patients with treatment-resistant major depressive disorder (MDD) who do not respond to multiple standard antidepressants. However, it remains unknown whether ketamine is equally effective in patients with MDD who previously also did not respond to electroconvulsive therapy (ECT). METHODS: This study compared 17 patients with treatment-resistant MDD who previously did not respond to ECT and 23 patients with treatment-resistant MDD who had not previously received ECT. All subjects received a single open-label infusion of ketamine (0.5 mg/kg). Patients were evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS) at baseline (60 min before the infusion), as well as at 40, 80, 120, and 230 min after infusion. RESULTS:Depressive symptoms were significantly improved in the ECT-resistant group at 230 minutes with a moderate effect size (p < .001, d = 0.50, 95% C.I.: 0.21-0.80). At 230 minutes, the non-ECT exposed group showed significant improvement with a large effect size (p < .001, d=1.00, 95% C.I.: 0.71-1.29). CONCLUSION:Ketamine appears to improve depressive symptoms in patients with MDD who had previously not responded to ECT. These preliminary results encourage further investigation with a larger sample size to determine effectiveness compared to other treatment-resistant patients with MDD. Published by Elsevier Inc.
Authors: Nancy Diazgranados; Lobna Ibrahim; Nancy E Brutsche; Andrew Newberg; Phillip Kronstein; Sami Khalife; William A Kammerer; Zenaide Quezado; David A Luckenbaugh; Giacomo Salvadore; Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate Journal: Arch Gen Psychiatry Date: 2010-08
Authors: H A Sackeim; R F Haskett; B H Mulsant; M E Thase; J J Mann; H M Pettinati; R M Greenberg; R R Crowe; T B Cooper; J Prudic Journal: JAMA Date: 2001-03-14 Impact factor: 56.272
Authors: Andrew D Krystal; Richard D Weiner; Margaret D Dean; Virginia H Lindahl; Louis A Tramontozzi; Grace Falcone; C Edward Coffey Journal: J Neuropsychiatry Clin Neurosci Date: 2003 Impact factor: 2.198
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney Journal: Annu Rev Pharmacol Toxicol Date: 2014 Impact factor: 13.820
Authors: Elia E Acevedo-Diaz; Grace W Cavanaugh; Dede Greenstein; Christoph Kraus; Bashkim Kadriu; Lawrence Park; Carlos A Zarate Journal: J Psychiatr Res Date: 2020-07-30 Impact factor: 4.791
Authors: Zuleide M Ignácio; Gislaine Z Réus; Camila O Arent; Helena M Abelaira; Meagan R Pitcher; João Quevedo Journal: Br J Clin Pharmacol Date: 2016-01-08 Impact factor: 4.335